clinical trial · NCT05621317
A Safety and Efficacy Study of PVX108 in Children and Adolescents With Peanut Allergy
Peanut AllergyPeanut HypersensitivityPeanut-Induced AnaphylaxisImmune System DiseasesPVX-108Placebo
brief summary
The overall aims of this study are to demonstrate that treatment with PVX108 immunotherapy has an acceptable safety profile and is effective for reducing clinical reactivity to peanut protein in children and adolescents with peanut allergy.
started
Feb 9, 2023
primary completion
Nov 1, 2025
completion
Jun 1, 2027
last updated
Oct 15, 2025
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol